Buchumschlag

Treatment of abdominal migraine in an 8‐year‐old child with calcitonin gene‐related peptide receptor antagonist: A case report

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Yunzhu Tang, Chunyan Lu, Yao Zhou, Shuxia Qian
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Headache: The Journal of Head and Face Pain
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment
von: Andrea M. Kuczynski, et al.
Veröffentlicht: (2025)

Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
von: Kara S. Graves, et al.
Veröffentlicht: (2026)

Potential drug interaction between calcitonin gene‐related peptide antagonists and neonatal Fc receptor inhibitors
von: Alex Harlan, et al.
Veröffentlicht: (2025)

Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
von: Samuel K. Peasah, et al.
Veröffentlicht: (2024)

Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists
von: Zoe Tasma, et al.
Veröffentlicht: (2025)

Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
von: Anna de Dios, et al.
Veröffentlicht: (2024)

Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
von: Alba López‐Bravo, et al.
Veröffentlicht: (2025)

Arterial hypertension: A safety risk of calcitonin gene‐related peptide ligand and receptor blocker class
von: David Croteau, et al.
Veröffentlicht: (2026)

Letter to the Editor regarding “Persistence, effectiveness, and tolerability of anti‐calcitonin gene‐related peptide monoclonal antibodies in patients with chronic migraine”
von: Joaquín Borrás‐Blasco, et al.
Veröffentlicht: (2025)

Migraine, idiopathic intracranial hypertension, and calcitonin gene‐related peptide antibodies
von: Irina Krikova, et al.
Veröffentlicht: (2024)

Differences in circulating alpha‐calcitonin gene–related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross‐sectional study
von: Marta Pascual‐Mato, et al.
Veröffentlicht: (2024)

The pathogenic role of calcitonin gene‐related peptide and predictors of new‐onset migraine and long‐term outcomes after transcatheter atrial septal defect closure
von: Tzu‐Hsuan Su, et al.
Veröffentlicht: (2024)

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
von: Jennifer Robblee, et al.
Veröffentlicht: (2024)

Amplifying and ameliorating light avoidance in mice with photoreceptor targeting and calcitonin gene‐related peptide sensitization
von: Eric A. Kaiser, et al.
Veröffentlicht: (2025)

Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
von: Gabriel Gárate, et al.
Veröffentlicht: (2024)

Author Response to Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
von: Ann I. Scher, et al.
Veröffentlicht: (2024)

Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update
von: Andrew C. Charles, et al.
Veröffentlicht: (2024)

Evaluating associations of migraine‐related vertigo
von: Nazia Karsan, et al.
Veröffentlicht: (2025)

Maternal and child mental health and incident migraine in adolescence: An “All Our Families” prospective cohort study
von: Kirsten Sjonnesen, et al.
Veröffentlicht: (2026)

A study of migraine‐like headache caused by topical aryl hydrocarbon receptor agonist tapinarof
von: Toshiyuki Hikita, et al.
Veröffentlicht: (2026)

Anxiety and depressive symptoms and migraine‐related outcomes in children and adolescents
von: Bilal Ahmed Rizvi, et al.
Veröffentlicht: (2024)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
von: Graham A. McLeod, et al.
Veröffentlicht: (2025)

Headache‐related disability as a function of migraine aura: A daily diary study
von: Delora E. Denney, et al.
Veröffentlicht: (2024)

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study
von: Julia Peris‐Subiza, et al.
Veröffentlicht: (2025)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
von: Rikki Mangrum, et al.
Veröffentlicht: (2024)

The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
von: Yunus Emre Meydanal, et al.
Veröffentlicht: (2025)

Three years of remote electrical neuromodulation (REN) acute treatment for migraine shows consistent effectiveness and no tachyphylaxis phenomenon
von: Stephanie J. Nahas, et al.
Veröffentlicht: (2025)

Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
von: Michael L. Garelja, et al.
Veröffentlicht: (2025)

Response to: Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
von: Alicia Alpuente, et al.
Veröffentlicht: (2026)

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study
von: Richard B. Lipton, et al.
Veröffentlicht: (2025)

Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy ( MOTS ) trial
von: Samantha C. Shao, et al.
Veröffentlicht: (2024)

Changes in brainstem habituation during onabotulinumtoxinA treatment in chronic migraine: A prospective case–control study
von: Gerlinde Freimark, et al.
Veröffentlicht: (2025)

A machine learning‐driven transcriptomic study reveals the key role of Romo1 in reversing central sensitization through stellate ganglion block in migraine: An interventional study based on a recurrent migraine rat model
von: Fei Yang, et al.
Veröffentlicht: (2025)

Afterimage duration differs for migraine with or without aura
von: Florian Rimmele, et al.
Veröffentlicht: (2025)

Mechanisms for mindfulness in migraine: Does catastrophizing matter?
von: Rebecca Erwin Wells, et al.
Veröffentlicht: (2024)

Useful considerations for treating migraine in patients with autism
von: Sinifunanya E. Nwaobi
Veröffentlicht: (2026)

Lifestyle triggers of migraine: Sleep restriction and caffeine lower the threshold for migraine‐like responses in rats in a sex‐specific manner
von: Gabriel Camargo de Oliveira, et al.
Veröffentlicht: (2026)

Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
von: Shuu‐Jiun Wang, et al.
Veröffentlicht: (2024)

No association between migraine and HLA alleles in a cohort of 13,210 individuals with migraine from the Danish Blood Donor Study
von: Inga Zalia Tummoszeit, et al.
Veröffentlicht: (2024)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
von: Chia‐Chun Chiang, et al.
Veröffentlicht: (2024)